These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32453139)

  • 1. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.
    Markman JD; Bolash RB; McAlindon TE; Kivitz AJ; Pombo-Suarez M; Ohtori S; Roemer FW; Li DJ; Viktrup L; Bramson C; West CR; Verburg KM
    Pain; 2020 Sep; 161(9):2068-2078. PubMed ID: 32453139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain.
    Kivitz AJ; Gimbel JS; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM
    Pain; 2013 Jul; 154(7):1009-21. PubMed ID: 23628600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial.
    Markman JD; Schnitzer TJ; Perrot S; Beydoun SR; Ohtori S; Viktrup L; Yang R; Bramson C; West CR; Verburg KM
    Pain Ther; 2022 Dec; 11(4):1267-1285. PubMed ID: 35962939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
    Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial.
    Dakin P; Kivitz AJ; Gimbel JS; Skrepnik N; DiMartino SJ; Emeremni CA; Gao H; Stahl N; Weinreich DM; Yancopoulos GD; Geba GP
    Ann Rheum Dis; 2021 Apr; 80(4):509-517. PubMed ID: 33199274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
    Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tanezumab in the treatment of chronic low back pain.
    Katz N; Borenstein DG; Birbara C; Bramson C; Nemeth MA; Smith MD; Brown MT
    Pain; 2011 Oct; 152(10):2248-2258. PubMed ID: 21696889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain.
    Gimbel JS; Kivitz AJ; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM
    Pain; 2014 Sep; 155(9):1793-1801. PubMed ID: 24937440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis.
    Fallon M; Sopata M; Dragon E; Brown MT; Viktrup L; West CR; Bao W; Agyemang A
    Oncologist; 2023 Dec; 28(12):e1268-e1278. PubMed ID: 37343145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
    Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
    Spierings ELH; Fidelholtz J; Wolfram G; Smith MD; Brown MT; West CR
    Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
    Berenbaum F; Langford R; Perrot S; Miki K; Blanco FJ; Yamabe T; Isogawa N; Junor R; Carey W; Viktrup L; West CR; Brown MT; Verburg KM
    Eur J Pain; 2021 Aug; 25(7):1525-1539. PubMed ID: 33728717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain: A Meta-analysis of Randomized Controlled Trials.
    Lian J; Wang J; Li X; Yang S; Li H; Zhong Y; Gao H; Chen G
    Clin Neuropharmacol; 2023 Jan-Feb 01; 46(1):6-16. PubMed ID: 36542785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
    Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
    J Pain; 2012 Aug; 13(8):790-8. PubMed ID: 22784777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study.
    Konno SI; Nikaido T; Markman JD; Ohta M; Machida T; Isogawa N; Yoshimatsu H; Viktrup L; Brown MT; West CR; Verburg KM
    Pain Manag; 2022 Apr; 12(3):323-335. PubMed ID: 34786956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.
    Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
    Arthritis Rheum; 2013 Jul; 65(7):1795-803. PubMed ID: 23553790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tanezumab in the treatment of pain from bone metastases.
    Sopata M; Katz N; Carey W; Smith MD; Keller D; Verburg KM; West CR; Wolfram G; Brown MT
    Pain; 2015 Sep; 156(9):1703-1713. PubMed ID: 25919474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Various Doses of Tanezumab in the Management of Chronic Low Back Pain (CLBP): A Pooled Analysis of 4,514 Patients.
    Tahir S; Sadik O; Ezenwa V; Iguh C; Ravichandran V; Ashraf NN; O'Connor EM; Sayabugari R
    Cureus; 2023 Oct; 15(10):e46790. PubMed ID: 37954824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.